Survival following lung transplantation for artificial stone silicosis relative to idiopathic pulmonary fibrosis.
BACKGROUND
Silicosis is a progressive lung disease resulting from the inhalation of respirable crystalline silica. Lung transplantation is the only treatment for end-stage silicosis. The aim of this study was to analyze the survival experience following lung transplantation among patients with silicosis.


METHODS
We reviewed data for all patients who underwent lung transplantation for silicosis and a matched group undergoing lung transplantation for idiopathic pulmonary fibrosis (IPF) at a single medical center between March 2006 and the end of December 2013. Survival was followed through 2015.


RESULTS
A total of 17 lung transplantations were performed for silicosis among 342 lung transplantations (4.9%) during the study period. We observed non-statistically significant survival advantage (hazard ratio 0.6; 95%CI 0.24-1.55) for those undergoing lung transplantation for silicosis relative to IPF patients undergoing lung transplantation during the same period.


CONCLUSIONS
Within the limits of a small sample, survival in silicosis patients following lung transplantation was not reduced compared to IPF. Am. J. Ind. Med. 60:248-254, 2017. © 2017 Wiley Periodicals, Inc.
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dror
D
Rosengarten
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Benjamin D
BD
Fox
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.|The Institute of Pulmonary and Allergic Diseases, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Elizabeth
E
Fireman
Division of Occupational and Environmental Medicine, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, California.
Paul D
PD
Blanc
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Victoria
V
Rusanov
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Oren
O
Fruchter
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yael
Y
Raviv
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Osnat
O
Shtraichman
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.|Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.
Milton
M
Saute
Institute of Pulmonology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Mordechai R
MR
Kramer
D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000601:surgery*; D016040:Lung Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012829:Silicosis / Q000209:etiology / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome
idiopathic pulmonary fibrosis; lung transplantation; occupational lung disease; silicosis; survival